SGX942 REDUCES THE DURATION OF SEVERE ORAL MUCOSITIS

O. Donini1, M. Kudrimoti2, A. Curtis3, S. Azawi4, F. Worden5, S. Katz6, J. Elder7
1Soligenix, Inc 2University of Kentucky 3Gibbs Cancer Center 4VA Long Beach Hospital 5University of Michigan Health System 6Wills-Knighton Cancer Center 7PharPoint Research

INTRODUCTION

SGX942 (dusquetide1,2) is a first-in-class Innate Defense Regulator3,4 with a novel mechanism of action, modulating the innate immune system to decrease inflammation and enhance bacterial clearance and tissue healing. Chemoradiation (CRT) associated OM has been linked to dysfunctional inflammation stimulated by innate immunity.

Head and neck cancer (HNC) patients receiving CRT are at high risk for ulcerative (WHO score ≥2) and severe (WHO score ≥3) OM. Severe OM (SOM) is associated with an inability to eat and/or drink, and may result in dehydration, infection, the need for parenteral nutrition, hospitalization and the interruption of CRT. It has an adversely affects quality of life for patients and has a significant pharmacoeconomic impact.

STUDY DESIGN

A double blind, placebo-controlled Phase 2 exploratory study in 111 HNC patients receiving at least 55 Gy radiation and cisplatin (weekly: 30-40 mg/m2; every 3rd week: 80-100 mg/m2) was conducted. Subjects were treated with study drug (placebo or SGX942 at 1.5 or 6.0 mg/kg) twice weekly with a 4-minute IV infusion. A 3.0 mg/kg dose group was included for dose escalation safety purposes only. OM (WHO score) was monitored twice weekly until end of radiation and then weekly for one month. Follow-up visits are ongoing.

SAFETY

No treatment emergent changes in vital signs, laboratory values, adverse events or serious adverse events were detected. In this patient population, SGX942 was safe and well-tolerated, consistent with the findings of the Phase 1 clinical study in 84 healthy volunteers.

Tumor status at the one-month follow-up visit favored the 1.5 mg/kg SGX942 treatment group.

Non-fungal infections were also decreased in the SGX942 treated groups, consistent with the preclinical data.

EFFICACY

In this exploratory Phase 2 study, statistical significance was prospectively defined as p<0.10. Duration was defined as the elapsed days between the first occurrence of OM and the last recorded occurrence of OM. Patients with no SOM were censored (duration = 0.1).

Both ulcerative OM (UOM) and SOM were evaluated and the largest impact observed in SOM.

Findings with the 1.5 mg/kg group were consistent across endpoints (incidence SOM, # days with SOM, onset SOM) and subpopulations (HPV+, HPV-, chemotheraphy regimen, etc.). Results with the 6.0 mg/kg were not consistent. In the Phase 1 trial, a similar non-linear dose response curve was observed with inflammatory markers.

CONCLUSIONS

• A non-linear dose response curve was observed, consistent with Phase 1 clinical and preclinical studies.

• SGX942 (1.5 mg/kg) decreased SOM 50% and 67% in patients at highest risk for SOM.

• SGX942 (6.0 mg/kg) was less effective treating OM, consistent with previous clinical and preclinical data.

• Consistent with preclinical work, SGX942 reduced incidence of infection.

• SGX942 did not interfere with tumor treatment, also consistent with preclinical xenograft studies.

• SGX942 was safe and well-tolerated in HNC cancer patients.

REFERENCES